Gallic acid, a naturally occurring polyphenol found in various plants, has been investigated for its anti-inflammatory and antioxidant properties. Several in vitro and animal studies have explored its potential in managing skin disorders, including psoriasis. Research indicates that gallic acid can inhibit pro-inflammatory cytokines such as TNF-α, IL-6, and IL-17, which play crucial roles in the pathogenesis of psoriasis. For example, a 2017 study published in “Molecular Medicine Reports” demonstrated that gallic acid reduced inflammation and keratinocyte proliferation in a mouse model of psoriasis-like skin lesions. Additionally, some in vitro research suggests that gallic acid can modulate oxidative stress and suppress pathways like NF-κB, further implicating its therapeutic potential.

However, it is important to note that, as of 2024, there have been no robust human clinical trials directly evaluating gallic acid as a treatment for psoriasis. The evidence is mostly preclinical, and its application in humans remains experimental. While the mechanistic rationale is strong and early results are promising, more rigorous studies, especially randomized controlled trials in humans, are required to establish efficacy and safety for this indication.